These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 18806523

  • 21. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
    Koncz I, Szél T, Jaeger K, Baczkó I, Cerbai E, Romanelli MN, Gy Papp J, Varró A.
    Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 24. Novel If current inhibitor ivabradine: safety considerations.
    Savelieva I, Camm AJ.
    Adv Cardiol; 2006 Nov; 43():79-96. PubMed ID: 16936474
    [Abstract] [Full Text] [Related]

  • 25. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study.
    Köster R, Kaehler J, Meinertz T, REDUCTION Study Group.
    Am Heart J; 2009 Oct; 158(4):e51-7. PubMed ID: 19781403
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

  • 29. The role of the funny current in pacemaker activity.
    DiFrancesco D.
    Circ Res; 2010 Feb 19; 106(3):434-46. PubMed ID: 20167941
    [Abstract] [Full Text] [Related]

  • 30. The funny current: cellular basis for the control of heart rate.
    DiFrancesco D, Borer JS.
    Drugs; 2007 Feb 19; 67 Suppl 2():15-24. PubMed ID: 17999560
    [Abstract] [Full Text] [Related]

  • 31. Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hypertrophic cardiomyopathy.
    Riesen SC, Schober KE, Smith DN, Otoni CC, Li X, Bonagura JD.
    Am J Vet Res; 2012 Feb 19; 73(2):202-12. PubMed ID: 22280379
    [Abstract] [Full Text] [Related]

  • 32. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr 19; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 33. The Clinical Use of Ivabradine.
    Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR.
    J Am Coll Cardiol; 2017 Oct 03; 70(14):1777-1784. PubMed ID: 28958335
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D, Camm JA.
    Drugs; 2004 Oct 03; 64(16):1757-65. PubMed ID: 15301560
    [Abstract] [Full Text] [Related]

  • 36. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
    Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D.
    J Physiol; 2006 Apr 15; 572(Pt 2):335-46. PubMed ID: 16484306
    [Abstract] [Full Text] [Related]

  • 37. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
    Petite SE, Bishop BM, Mauro VF.
    Am J Ther; 2018 Apr 15; 25(2):e247-e266. PubMed ID: 26910057
    [Abstract] [Full Text] [Related]

  • 38. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina.
    Fox K.
    Expert Opin Pharmacother; 2006 Jun 15; 7(9):1211-20. PubMed ID: 16732707
    [Abstract] [Full Text] [Related]

  • 39. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U.
    Circulation; 2008 May 06; 117(18):2377-87. PubMed ID: 18443241
    [Abstract] [Full Text] [Related]

  • 40. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr 06; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.